glp-1 obesity drug news today october 16 2025 trends 2025: real-world data, patient outcomes & future therapies Harnessing GLP-1 Receptor Agonists for

Techniques like ion-pairing reversed-phase liquid chromatography (IP-RPLC) are widely used to monitor peptide critical quality attributes (CQAs), with hyphenated LC-MS approaches playing a key role in enhancing sensitivity and selectivity, enabling quantification of low-level impurities

[DOI] [PMC free article] [PubMed] [Google Scholar] 182.Ling C.H.Y., de Craen A.J.M., Slagboom P.E., Gunn D.A., Stokkel M.P.M., Westendorp R.G.J., Maier A.B

Over time, the GLP-1 population has evolved to include an increasing prevalence of patients with no prior antidiabetic prescriptions and with fewer diabetes diagnoses

Then, in September, the Trump Administration launched a crackdown on deceptive direct-to-consumer drug advertising, resulting in the FDA publishing over 55 warning letters to online sellers of compounded versions of GLP-1 medications that called for the removal of false and misleading promotional statements, claims of clinically proven weight-loss treatments, and using the words FDA-approved in advertising copy

These may have ingredients like berberine, cinnamon, garcinia, etc., which claim to help manage appetite, reduce insulin resistance, manage blood sugar levels and support overall wellness 9 , 10 , 12